Fibrobiologics, Inc. insider trading
Every open-market purchase and sale by Fibrobiologics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $120,493 7 trades by 4 insiders
3 months later: median −85.8% (−96.2% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Fibrobiologics, Inc.’s insiders pay?
From August 12, 2024 to March 5, 2026, 4 insiders reported 8 open-market purchases and 0 sales not made under a pre-set plan in Fibrobiologics, Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Khoja Hamid | Chief Scientific Officer | 3 | — | — | 0 | — | March 5, 2026 |
| Garcia Ruben A | General Counsel | 2 | — | — | 0 | — | March 2, 2026 |
| O'heeron Pete | CHIEF EXECUTIVE OFFICER | 2 | — | — | 0 | — | March 4, 2026 |
| Davis Jason | Chief Financial Officer | 1 | — | — | 0 | — | March 3, 2026 |